Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- SunTrust Robinson Humphrey Upgrades Twitter, Inc. (TWTR) to Buy
- Recent Market Correction Seen as 'Extremely Unusual'
- Wall St. dips as September rate hike back on the table
- Amicus Therapeutics (FOLD) to Acquire Scioderm in ~$950M Deal
- Buffett's Berkshire Hathaway Discloses ~$4.5B Stake in Phillips 66 (PSX)
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intercept Pharma's (ICPT) OCA NDA Accepted for Priority Review by U.S. FDA
- ATARA Biotherapeutics (ATRA) Completes Enrollment in PINTA 745 Phase 2 as ESRD Treatment
- Sunshine Heart (SSH) Announced Receipt of FDA Approval for COUNTER HF Amendment
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!